Cancer Imaging is the official journal of the International Cancer Imaging Society (ICIS)
Articles
Page 4 of 20
-
Citation: Cancer Imaging 2014 14(Suppl 1):O1
-
Prostate-MRI: experience of the observer and technical conditions influence the cancer detection rate
Citation: Cancer Imaging 2014 14(Suppl 1):S2 -
Global challenges of cancer imaging: perspective from different parts of the world: Asia
Citation: Cancer Imaging 2014 14(Suppl 1):O3 -
Agreement of diameter- and volume-based pulmonary nodule management in CT lung cancer screening
Citation: Cancer Imaging 2014 14(Suppl 1):S4 -
What is the importance of solitary focal bony FDG-uptake on 18F-FDG PET-CT of known cancer patients?
Citation: Cancer Imaging 2014 14(Suppl 1):P6 -
Staging of lung cancer CT and PET
Citation: Cancer Imaging 2014 14(Suppl 1):O6 -
Patient outcome after pulmonary radiofrequency ablation: a prospective analysis of results from a single centre
Citation: Cancer Imaging 2014 14(Suppl 1):P8 -
Screening & staging of colorectal cancer
Citation: Cancer Imaging 2014 14(Suppl 1):O8 -
Chemotherapy response evaluation in metastatic non-small cell lung carcinoma (NSCLC) with 18F- FDG PET/CT and CT scan
Citation: Cancer Imaging 2014 14(Suppl 1):P10 -
PSMA ligands for diagnosis and therapy of prostate cancer
Citation: Cancer Imaging 2014 14(Suppl 1):O10 -
Multiparametrical diffusion weighted imaging for the detection of anaplastic transformation of low-grade gliomas
Citation: Cancer Imaging 2014 14(Suppl 1):S11 -
Clinical management of patients with complicated multifocal disease
Citation: Cancer Imaging 2014 14(Suppl 1):O11 -
Prostate-MRI: experience of the observer and technical conditions influence the cancer detection rate
Citation: Cancer Imaging 2014 14(Suppl 1):P12 -
The do’s and dont’s of liver CT and MR imaging
Citation: Cancer Imaging 2014 14(Suppl 1):O12 -
Dynamic 18FDG PET/CT and dynamic contrast enhanced MRI of locally advanced breast cancer
Citation: Cancer Imaging 2014 14(Suppl 1):P14 -
Pediatric tumours: pseudotumour or a tumour?
Citation: Cancer Imaging 2014 14(Suppl 1):O14 -
Neuroblastoma and nephroblastoma: an overview and comparison
Citation: Cancer Imaging 2014 14(Suppl 1):O15 -
What the radiologist needs to know about restaging of rectal carcinoma after chemoradiation therapy
Citation: Cancer Imaging 2014 14(Suppl 1):P16 -
Pediatric tumours: liver tumours
Citation: Cancer Imaging 2014 14(Suppl 1):O16 -
Diagnostic accuracy of staging of Wilms’ tumour in the era of multislice CT
Citation: Cancer Imaging 2014 14(Suppl 1):P18 -
Ovarian cancer: imaging in treatment selection and planning with FIGO update
Citation: Cancer Imaging 2014 14(Suppl 1):O18 -
Radiological characteristics of screen-detected lung cancers: predictive for histological subtype?
Citation: Cancer Imaging 2014 14(Suppl 1):P20 -
Complications following locoregional therapy of renal cancer
Citation: Cancer Imaging 2014 14(Suppl 1):O21 -
Fast venous return in inferior mesenteric vein: a new sign for rectosigmoid carcinoma on CT
Citation: Cancer Imaging 2014 14(Suppl 1):P22 -
Whole-body DWI in patients with lymphoma: imaging findings, pitfalls, and limitations
Citation: Cancer Imaging 2014 14(Suppl 1):O22 -
Utility of dual time point 18 FDG PET-CT
Citation: Cancer Imaging 2014 14(Suppl 1):P24 -
Management of solid and sub-solid lung nodules
Citation: Cancer Imaging 2014 14(Suppl 1):O24 -
Session: Evaluation of lung nodules: role of PET/CT
Citation: Cancer Imaging 2014 14(Suppl 1):O25 -
Characterization and management of cystic pancreatic neoplasms communicating lesions (IPMN)
Citation: Cancer Imaging 2014 14(Suppl 1):O26 -
Noncommunicating cystic pancreatic lesions (i.e. serous and mucinous cystadenoma + rare lesions)
Citation: Cancer Imaging 2014 14(Suppl 1):O27 -
Imaging neuroendocrine tumours of the pancreas: role of CT and MRI
Citation: Cancer Imaging 2014 14(Suppl 1):O28 -
Role of molecular imaging in the detection of neuroendocrine tumour
Citation: Cancer Imaging 2014 14(Suppl 1):O29 -
Cancer imaging in the era of precision treatment: present and future
Citation: Cancer Imaging 2014 14(Suppl 1):O30 -
Whole-body MRI and diffusion MRI
Citation: Cancer Imaging 2014 14(Suppl 1):O31 -
Hybrid imaging with PET/CT and PET/MR
Citation: Cancer Imaging 2014 14(Suppl 1):O32 -
Beyond the image : sense and non-sense in imaging biomarkers
Citation: Cancer Imaging 2014 14(Suppl 1):O33 -
Evaluation of hepatic flow changes in early stages after extended hepatectomy by contrast enhanced ultrasound
Citation: Cancer Imaging 2014 14(Suppl 1):P35 -
Response assessment in daily practice: RECIST and its modifications
Citation: Cancer Imaging 2014 14(Suppl 1):O35 -
Imaging tumour response: beyond RECIST
Citation: Cancer Imaging 2014 14(Suppl 1):O36 -
Imaging manifestations of unusual side effects of new anticancer medications
Citation: Cancer Imaging 2014 14(Suppl 1):P37 -
Abdominal and pelvic complications of molecular targeted therapy
Citation: Cancer Imaging 2014 14(Suppl 1):O37 -
Lung, CNS and musculo-skeletal targeted therapy-induced toxicity: imaging features
Citation: Cancer Imaging 2014 14(Suppl 1):O38 -
Modern technology: lowering the radiation dose for lung cancer screening
Citation: Cancer Imaging 2014 14(Suppl 1):P39 -
Comprehensive breast MRI: an update
Citation: Cancer Imaging 2014 14(Suppl 1):O39 -
Contributions of multimodal imaging
Citation: Cancer Imaging 2014 14(Suppl 1):O40 -
Role of dual phase MDCT in renal cancer – beyond the renal mass
Citation: Cancer Imaging 2014 14(Suppl 1):P41 -
Pleura and lung
Citation: Cancer Imaging 2014 14(Suppl 1):O41 -
Incidental findings in the oncology patient: pancreas and spleen
Citation: Cancer Imaging 2014 14(Suppl 1):O43 -
Adrenal masses in oncology patients
Citation: Cancer Imaging 2014 14(Suppl 1):O45 -
Whole-body DWI in practice
Citation: Cancer Imaging 2014 14(Suppl 1):O47
Official journal of
Follow
Annual Journal Metrics
-
2022 Citation Impact
4.9 - 2-year Impact Factor
4.7 - 5-year Impact Factor
1.636 - SNIP (Source Normalized Impact per Paper)
1.231 - SJR (SCImago Journal Rank)2023 Speed
13 days submission to first editorial decision for all manuscripts (Median)
123 days submission to accept (Median)2023 Usage
1,045,188 downloads
349 Altmetric mentions